| Title | Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder. | | Author(s) | Dmochowski RR, Rosenberg MT, Zinner NR, Staskin DR, Sand PK | | Institution | Vanderbilt University School of Medicine, Nashville, TN, USA. | | Source | Value Health 2009 Oct 8. | | Abstract | ABSTRACT
Objectives: Overactive bladder syndrome (OAB) is a urinary condition that often exerts detrimental effects on an individual's quality of life (QoL). A once-daily, extended-release (ER) formulation of the quaternary amine trospium chloride has recently been developed for the treatment of OAB. The pooled health-related QoL (HRQoL) data from two multicenter, parallel-group, double-blind Phase III studies with trospium chloride ER 60 mg were analyzed.
Methods: Subjects aged >/=18 years with urinary urgency, frequency, and an average of >/=1 urge urinary incontinence episode per day on a 3-day bladder diary were randomized (1:1) to receive once-daily trospium 60 mg ER or placebo for 12 weeks. HRQoL was assessed at baseline and at Week 12 using the King's Health Questionnaire (KHQ) and the OAB questionnaire (OAB-q).
Results: Overall, 1165 subjects were randomized (trospium ER, n = 578; placebo, n = 587). Trospium ER produced significantly greater improvements from baseline than placebo in seven of the nine KHQ domains. At Week 12, the improvement in mean OAB-q HRQoL total score (from approximately 52 at baseline) was significantly greater with trospium ER than with placebo (+25.8 vs. +20.7; P = 0.0003). Improvements from baseline were seen with trospium ER on all eight of the OAB-q symptom bother scales.
Conclusions: Once-daily trospium 60 mg ER improved the QoL of subjects with OAB, as assessed using the KHQ and the OAB-q, in two large Phase III clinical trials. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19818062 |
|
